US equities |
MU $896.07 ▼-0.98% SPCX $147.79 ▼-0.11% NVDA $216.47 ▼-0.29% AAPL $339.50 ▼-1.00% TSLA $373.71 ▲+1.54% META $694.25 ▼-1.59% AMZN $262.63 ▲+0.07% SNDK $1,365.38 ▼-0.42%
FinancialContent

Articles published by Merck & Co., Inc.

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
News headline image
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Acquire EyeBio
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Third-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces First-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Animal Health to Acquire Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Tickers ELAN MRK
News headline image
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >